Under the collaboration, researchers from Metabolon and Mass General will work on identifying unique metabolic signatures for ALS as a means of developing a diagnostic test using biomarkers in cerebrospinal fluid and blood, the company said.
The study, being funded by the National Institute of Neurological Disorders and Stroke, is called Metabolic Signatures in ALS. Specific details of the Mass General collaboration were not disclosed.